RE:RE:RE:Sanofi's M&A plans of insulin company hit by FTC delayWhichever Big Pharma company that acquires ONCY's pelareorep, once pelareorep receives approval for one indication, in either breast or pancreatic cancer for example, that Big Pharma company will take whatever time it needs to obtain additional approvals with other I/O agents including subcutaneous PD-1 immune checkpoint inhibitors like Pfizer's sasanlimab, and in the process will be gaining the commensurate FDA 13 years of marketing approval for each indication approved.
OR Pelareorep may be acquired by a Big Pharma company like Pfizer that could remained involved in ONCY's registration trials (and subsequent Accelerated Approvals) by acquiring ONCY/pelareorep and then entering into a licensing agreement for pelareorep by any other Big Pharma company. like MerckKGaA or Roche, as example. The same acquisition/out-licensing scenario can be true for other Big Pharma companies who ultimately acquire ONCY.
Additionally ONCY's potential acquirer will have the ability to out-license pelareorep to other Big Pharma companies who will further conduct combinational clinical trials with I/O agents that those 'licensees' determine critical for their I/O agents' development and ultimate marketing approval.